PROTAGONIST THERAPEUTICS INC (PTGX)

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate

Protagonist Therapeutics Enters Oversold Territory (PTGX)

Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis

Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Interesting PTGX Put And Call Options For July 2025

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024

PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagonist Therapeutics (NASDAQ:PTGX) just reported results for the second qua...

Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor

Interesting PTGX Put And Call Options For September 20th

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

3 Growth Stocks No One Is Watching (But They Should Be)

While overlooked growth stocks present high risks, it’s difficult to find any other sector with as much upside potential.

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Protagonist Therapeutics will join the SmallCap 600 on Wednesday.

First Week of August 16th Options Trading For Protagonist Therapeutics (PTGX)

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

The 3 Best Biotech Stocks to Buy in June 2024

Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia.

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024

PTGX stock results show that Protagonist Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Protagonist Therapeutics (NASDAQ:PTGX) just reported results for the first quar...

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

Turnstone Biologics Appoints William Waddill to its Board of Directors

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera